118 related articles for article (PubMed ID: 26586447)
1. Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
Glenn KJ; Yu LJ; Reddy MB; Fretland AJ; Parrott N; Hussain S; Palacios M; Vazvaei F; Zhi J; Tuerck D
Xenobiotica; 2016 Aug; 46(8):667-76. PubMed ID: 26586447
[TBL] [Abstract][Full Text] [Related]
2. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.
Zhou Z; Zalutsky MR; Chitneni SK
Mol Pharm; 2021 Oct; 18(10):3871-3881. PubMed ID: 34523337
[TBL] [Abstract][Full Text] [Related]
6. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
Ding Q; Zhang Z; Liu JJ; Jiang N; Zhang J; Ross TM; Chu XJ; Bartkovitz D; Podlaski F; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
J Med Chem; 2013 Jul; 56(14):5979-83. PubMed ID: 23808545
[TBL] [Abstract][Full Text] [Related]
7. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.
Higgins B; Glenn K; Walz A; Tovar C; Filipovic Z; Hussain S; Lee E; Kolinsky K; Tannu S; Adames V; Garrido R; Linn M; Meille C; Heimbrook D; Vassilev L; Packman K
Clin Cancer Res; 2014 Jul; 20(14):3742-52. PubMed ID: 24812409
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A; Miller WH; Blay JY; Gietema JA; Bang YJ; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL; Chen LC; Petry C; Yang QJ; Schmitt C; Jamois C; Siu LL
Invest New Drugs; 2021 Dec; 39(6):1587-1597. PubMed ID: 34180037
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D
Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Abdul Razak AR; Miller WH; Uy GL; Blotner S; Young AM; Higgins B; Chen LC; Gore L
Invest New Drugs; 2020 Aug; 38(4):1156-1165. PubMed ID: 31734832
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Chen L; Pastorino F; Berry P; Bonner J; Kirk C; Wood KM; Thomas HD; Zhao Y; Daga A; Veal GJ; Lunec J; Newell DR; Ponzoni M; Tweddle DA
Int J Cancer; 2019 Jun; 144(12):3146-3159. PubMed ID: 30536898
[TBL] [Abstract][Full Text] [Related]
12. A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [
Pápai Z; Chen LC; Da Costa D; Blotner S; Vazvaei F; Gleave M; Jones R; Zhi J
Cancer Chemother Pharmacol; 2019 Jul; 84(1):93-103. PubMed ID: 31062077
[TBL] [Abstract][Full Text] [Related]
13. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
[TBL] [Abstract][Full Text] [Related]
15. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Uy GL; Assouline S; Young AM; Blotner S; Higgins B; Chen LC; Yee K
Invest New Drugs; 2020 Oct; 38(5):1430-1441. PubMed ID: 32020437
[TBL] [Abstract][Full Text] [Related]
17. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
Ciardullo C; Aptullahoglu E; Woodhouse L; Lin WY; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Haematologica; 2019 Dec; 104(12):2429-2442. PubMed ID: 31004033
[TBL] [Abstract][Full Text] [Related]
18. Oral idasanutlin in patients with polycythemia vera.
Mascarenhas J; Lu M; Kosiorek H; Virtgaym E; Xia L; Sandy L; Mesa R; Petersen B; Farnoud N; Najfeld V; Rampal R; Dueck A; Hoffman R
Blood; 2019 Aug; 134(6):525-533. PubMed ID: 31167802
[TBL] [Abstract][Full Text] [Related]
19. Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients.
So WV; Ou Yang TH; Yang X; Zhi J
Cancer Chemother Pharmacol; 2019 Jan; 83(1):209-213. PubMed ID: 30511219
[TBL] [Abstract][Full Text] [Related]
20. Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin.
Zhu D; Guo H; Chang Y; Ni Y; Li L; Zhang ZM; Hao P; Xu Y; Ding K; Li Z
Angew Chem Int Ed Engl; 2018 Jul; 57(30):9284-9289. PubMed ID: 29768700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
